Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells - PubMed (original) (raw)
Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells
R J North et al. J Exp Med. 1984.
Abstract
It was shown that the progressive growth of the immunogenic meth A fibrosarcoma in its semisyngeneic host results in the generation of concomitant immunity to the growth of a tumor implant. The generation of immunity occurred between days 6 and 9 of tumor growth and was associated with the generation of sensitized T cells that were capable, on passive transfer, of causing regression of a 3-d tumor in gamma-irradiated recipients. After day 9 of tumor growth, concomitant immunity and the T cells able to passively transfer it were progressively lost, and this was associated with the generation of splenic suppressor T cells able to suppress the expression of adoptive immunity against an established tumor in T cell-deficient ( TXB ) recipients. The T cells that passively transferred concomitant immunity were shown to be of the Ly-1-2+ phenotype, in contrast to the T cells that transferred suppression, which were shown with the same reagents to be Ly-1+2-. The results are consistent with the hypothesis that the progressive growth of an immunogenic tumor results in the generation of Ly-1-2+-sensitized effector T cells that fail to reach a number sufficient to destroy the tumor because their generation is down-regulated by tumor-induced Ly-1+2- suppressor T cells.
Similar articles
- Specific adoptive immunotherapy: experimental basis and future potential.
Greenberg PD, Cheever MA, Fefer A. Greenberg PD, et al. Surv Immunol Res. 1982;1(1):85-90. doi: 10.1007/BF02918244. Surv Immunol Res. 1982. PMID: 6764836 Review. No abstract available. - The LY-6 locus: a multigene family encoding phosphatidylinositol-anchored membrane proteins concerned with T-cell activation.
Rock KL, Reiser H, Bamezai A, McGrew J, Benacerraf B. Rock KL, et al. Immunol Rev. 1989 Oct;111:195-224. doi: 10.1111/j.1600-065x.1989.tb00547.x. Immunol Rev. 1989. PMID: 2697681 Review. No abstract available.
Cited by
- Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help.
Medler TR, Kramer G, Bambina S, Gunderson AJ, Alice A, Blair T, Zebertavage L, Duhen T, Duhen R, Young K, Crittenden MR, Gough MJ. Medler TR, et al. Sci Rep. 2023 Apr 18;13(1):6277. doi: 10.1038/s41598-023-33508-1. Sci Rep. 2023. PMID: 37072485 Free PMC article. - Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.
Norouzian M, Mehdipour F, Ashraf MJ, Khademi B, Ghaderi A. Norouzian M, et al. BMC Immunol. 2022 Nov 15;23(1):56. doi: 10.1186/s12865-022-00530-3. BMC Immunol. 2022. PMID: 36376825 Free PMC article. - Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.
Ding Y, Wang Z, Zhou F, Chen C, Qin Y. Ding Y, et al. Front Oncol. 2022 Sep 30;12:987302. doi: 10.3389/fonc.2022.987302. eCollection 2022. Front Oncol. 2022. PMID: 36248998 Free PMC article. Review. - Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics.
Dwivedi M, Tiwari S, Kemp EH, Begum R. Dwivedi M, et al. Heliyon. 2022 Aug 27;8(8):e10450. doi: 10.1016/j.heliyon.2022.e10450. eCollection 2022 Aug. Heliyon. 2022. PMID: 36082331 Free PMC article. Review.
References
- J Exp Med. 1982 Nov 1;156(5):1398-414 - PubMed
- J Reticuloendothel Soc. 1982 Jul;32(1):25-35 - PubMed
- Ann N Y Acad Sci. 1982;392:300-8 - PubMed
- Springer Semin Immunopathol. 1982;5(2):175-92 - PubMed
- J Exp Med. 1983 May 1;157(5):1448-60 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources